Literature DB >> 22084425

Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer.

Jodi Speiser1, Kimberly Foreman, Eva Drinka, Constantine Godellas, Claudia Perez, Alia Salhadar, Çağatay Erşahin, Prabha Rajan.   

Abstract

Triple-negative breast cancer (TNBC) demonstrates lack of expression of hormone receptors and human epidermal growth factor receptor. However, there is no targeted therapy for TNBC. The authors analyzed 29 TNBC cases for Notch-1 and Notch-4 biomarker expression and subcellular location, Ki67 proliferation rate, and relevant clinical/survival data. Results demonstrated an unfavorable Ki67 rate in 90% of cases, Notch-1 expression in tumor and endothelial cells in 100% of cases, and Notch-4 expression in tumor cells in 73% of cases and endothelial cells in 100% of cases. Additionally, subcellular localization of Notch-1 and Notch-4 was predominantly nuclear and cytoplasmic. In conclusion, (a) the majority of TNBCs are high-grade infiltrating ductal carcinomas with high Ki67 proliferation rate and (b) both Notch-1 and Notch-4 receptors are overexpressed in tumor and vascular endothelial cells with subcellular localization different from that of hormone-positive breast cancer. Targeting Notch signaling with gamma secretase inhibitors should to be explored to further improve the survival rate of TNBC patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084425     DOI: 10.1177/1066896911427035

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  38 in total

Review 1.  Therapeutic targets of triple-negative breast cancer: a review.

Authors:  Vinayak S Jamdade; Nikunj Sethi; Nitin A Mundhe; Parveen Kumar; Mangala Lahkar; Neeraj Sinha
Journal:  Br J Pharmacol       Date:  2015-07-30       Impact factor: 8.739

2.  Inhibition of Notch signaling alters the phenotype of orthotopic tumors formed from glioblastoma multiforme neurosphere cells but does not hamper intracranial tumor growth regardless of endogene Notch pathway signature.

Authors:  Karina Kristoffersen; Mette Kjølhede Nedergaard; Mette Villingshøj; Rehannah Borup; Helle Broholm; Andreas Kjær; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

3.  Notch1 single nucleotide polymorphism rs3124591 is associated with the risk of development of invasive ductal breast carcinoma in a Chinese population.

Authors:  Yu-Wen Cao; Guo-Xing Wan; Chun-Xia Zhao; Jian-Ming Hu; Li Li; Wei-Hua Liang; Wen-Qin Li; Yu-Cong Li; Yi-Xiao Li; Xiao-Ming Du; Shi-Ying Yu; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.

Authors:  Bilge Aktas; Hongxia Sun; Hui Yao; Weiwei Shi; Rebekah Hubbard; Ya Zhang; Tingting Jiang; Sophia N Ononye; Vikram B Wali; Lajos Pusztai; W Fraser Symmans; Christos Hatzis
Journal:  Mol Oncol       Date:  2014-02-17       Impact factor: 6.603

5.  Modulation of apoptosis-related cell signalling pathways by curcumin as a strategy to inhibit tumor progression.

Authors:  Jin Chen; Feng-Ling Wang; Wei-Dong Chen
Journal:  Mol Biol Rep       Date:  2014-03-07       Impact factor: 2.316

Review 6.  Nanoparticles for Manipulation of the Developmental Wnt, Hedgehog, and Notch Signaling Pathways in Cancer.

Authors:  D M Valcourt; M N Dang; J Wang; E S Day
Journal:  Ann Biomed Eng       Date:  2019-11-04       Impact factor: 3.934

Review 7.  Arsenic trioxide: insights into its evolution to an anticancer agent.

Authors:  Maneka Hoonjan; Vaibhav Jadhav; Purvi Bhatt
Journal:  J Biol Inorg Chem       Date:  2018-02-02       Impact factor: 3.358

8.  Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.

Authors:  Shubing Zhang; Wen-cheng Chung; Lucio Miele; Keli Xu
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

9.  Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer.

Authors:  He Zhu; Feriyl Bhaijee; Nivin Ishaq; Dominique J Pepper; Kandis Backus; Alexandra S Brown; Xinchun Zhou; Lucio Miele
Journal:  Am J Cancer Res       Date:  2013-04-03       Impact factor: 6.166

10.  Mammary cancer chemoprevention by withaferin A is accompanied by in vivo suppression of self-renewal of cancer stem cells.

Authors:  Su-Hyeong Kim; Shivendra V Singh
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.